- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells
© Li et al; licensee BioMed Central Ltd. 2009
Received: 2 March 2009
Accepted: 16 October 2009
Published: 16 October 2009
Aberrant activity of tyrosine-phosphorylated proteins is commonly associated with HCC metastasis. Cell signaling events driven by these proteins are implicated in numerous processes that alter cancer cell behavior. Exploring the activities and signaling pathways of these proteins in HCC metastasis may help in identifying new candidate molecules for HCC-targeted therapy.
Hep3B (a nonmetastatic HCC cell line) and MHCC97H (a highly metastatic HCC cell line) were used in this study, and the tyrosine-phosphorylated proteins expressed in these cell lines were profiled by a phosphoproteomics technique based on LC-MS/MS. Protein-protein interaction and functional clustering analyses were performed to determine the activities of the identified proteins and the signaling pathways closely related to HCC metastasis.
In both cell lines, a total of 247 phosphotyrosine (pTyr) proteins containing 281 pTyr sites were identified without any stimulation. The involvement of almost 30% of these in liver or liver cancer has not been reported previously. Biological process clustering analysis indicated that pTyr proteins involved in cell motility, migration, protein autophosphorylation, cell-cell communication, and antiapoptosis functions were overexpressed during metastasis. Pathway clustering analysis revealed that signaling pathways such as those involved in EGFR signaling, cytokine- and chemokine-mediated signal transduction, and the PI3K and JAK-STAT cascades were significantly activated during HCC metastasis. Moreover, noncanonical regulation of the JNK cascade might also provide new targets for HCC metastasis. After comparing the pTyr proteins that were differentially expressed during HCC cell metastasis, we selected FER, a nonreceptor tyrosine kinase, and validated its role in terms of both expression and function. The data confirmed that FER might play a critical role in the invasion and metastasis of HCC.
The identification of pTyr proteins and signaling pathways associated with HCC metastasis could provide useful information for selecting new molecular intervention targets. Moreover, FER might serve as a novel drug target in future HCC therapy.
Hepatocellular carcinoma (HCC) is one of the most malignant solid tumors and ranks fourth in terms of mortality and fifth in terms of morbidity among various human cancers worldwide . The short-term prognosis of this condition has dramatically improved due to early diagnosis and surgical resection, transplantation, and local ablation therapy. However, long-term survival is still poor due to frequent intrahepatic metastasis and distant metastasis. Therefore, determining the mechanism of HCC metastasis is a major challenge and impeding the progression of this tumor at an early stage is essential for improving the prognosis of HCC.
Protein tyrosine phosphorylation is an important posttranslational modification that plays a critical role in signal transduction associated with cell proliferation, survival, apoptosis, mobility, adhesion, etc. Tyrosine-phosphorylated proteins (also known as phosphotyrosine proteins, pTyr) include a wide range of signal molecules, such as receptor tyrosine kinases, adapter proteins, and scaffold proteins, which are known to be involved in the cancer metastatic process [2–7]. Aberrant expression and activity of pTyr proteins in the cell signaling pathway have been reported in various human cancers [5, 6, 8–11]. In recent years, several kinase inhibitors have been introduced for molecular target therapy in clinical oncology. These act by interfering with the activity of specific signaling pathways [9, 10, 12]. Therefore, exploring and analyzing the expression profiles of pTyr proteins in HCC cells by a high-throughput method would be extremely useful for obtaining insights into the mechanisms of HCC metastasis and recurrence. Such studies would also help in identifying new drug targets for HCC therapy.
In the post-genome era, proteomics techniques based on LC-MS/MS enable us to study the complete range of signal proteins present in a set of cells or tissues under specific conditions [13–15]. In this study, pTyr proteins were identified, and a comparative study was performed between a nonmetastatic HCC cell line (Hep3B) and an HCC cell line with high metastatic potential (MHCC97H). Several biological processes and signaling pathways were found to be strongly correlated with HCC metastasis. Among the differentially expressed pTyr proteins, FER, a nonreceptor tyrosine kinase, appears to be an important protein involved in HCC metastasis.
The Hep3B cell line (nonmetastatic human HCC cells) was obtained from Cornell University, USA, and grown in MEM medium supplemented with 10% fetal bovine serum (PAA) in a 5.0% CO2 incubator at 37°C. The MHCC97H cell line (highly metastatic human HCC cells) was established in the Liver Cancer Institute, Zhongshan Hospital, Fudan University . These cells were sustained in DMEM medium supplemented with 10% fetal bovine serum (PAA) in a 5.0% CO2 incubator at 37°C. The two cell lines have an integrated HBV DNA genome and exhibit positive alpha-fetoprotein (AFP) expression. These cell lines are commonly used as model cell lines in HCC studies [17–20].
Immunoprecipitation of pTyr proteins
Cells that had grown to approximately 90% confluency were subcultured. The subcultured cells were grown to approximately 80% confluency and starved in serum-free medium for 12 h to reduce the phosphorylation background resulting from the culture conditions. The cells were placed in a 10-cm dish, washed twice with chilled PBS, and lysed by incubation in 1 ml modified RIPA lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, and 1 mM EDTA supplemented with 1 mM sodium orthovanadate, 10 mM sodium fluoride, 10 mM glycerophosphate, and 5 mM sodium pyrophosphate) for 30 min on ice. The cell lysate was cleared by centrifugation at 15,000 rpm for 30 min at 4°C, and the protein concentration was determined by the DC Protein Assay kit (Bio-Rad).
Anti-pTyr specific immuoprecipitation was performed with two different anti-pTyr antibodies. The phosphotyrosine monoclonal antibody pTyr-100 (Cell Signaling Technology) and/or 4G10 (Upstate) was noncovalently conjugated to Protein A-agarose (Sigma) at a concentration of 1 mg/ml beads by overnight incubation at 4°C with gentle shaking. After coupling, the antibody resin was washed twice with PBS and then three times with modified RIPA buffer (5 bead volumes of buffer for each wash). To confirm that efficient coupling had been achieved, an aliquot of the antibody resin was boiled in SDS-PAGE sample buffer for 5 min, and the yield of the released antibody was determined by running it along side a purified antibody standard on SDS-PAGE. The gels were stained with Coomassie blue. The immobilized antibody (400 μl, 400 μg) was added in the form of a 1:1 slurry in modified RIPA buffer to 50 mg cell lysate (1 mg/ml) that had been precleared with 800 μl Protein A-agarose at 4°C for 6 h. The mixture was incubated overnight at 4°C with gentle shaking. The immunocomplex beads were then harvested by centrifugation at 3,000 rpm and 4°C for 5 min and washed three times with 10 bead volumes of modified RIPA buffer. Finally, pTyr-containing proteins were eluted three times with 500 μl of elution buffer (8 M urea, 50 mM NH4HCO3, and 20 mM ethylamine) for 5 min each at 96°C, and the eluates were combined.
Desalting and tryptic digestion of pTyr-containing proteins
The pTyr-containing proteins were reduced and alkylated by the ProteoPrep™ Reduction and Alkylation Kit (Sigma) according to the manufacturer's instructions. Briefly, the protein sample was reduced by incubation with 5 mM ributylphosphine (TBP) at room temperature for 30 min. The protein solution was then alkylated by adding 15 mM iodoacetamide and incubating in the dark for 1 h at room temperature. The excess iodoacetamide in the reaction mixture was quenched by additional incubation with 5 mM TBP for 15 min at room temperature. Subsequently, the protein mixture was desalted on a PD-10 desalting column, as recommended by the manufacturer (GE Healthcare), and the buffer was exchanged with a 50 mM NH4HCO3 solution. Trypsin (modified sequencing grade; Promega, Madison, WI) digestion was performed at a 1:50 trypsin-to-protein ratio (w/w) for 16 h at 37°C. The tryptic peptides were then dried in a Speed Vac.
Immobilized metal affinity chromatography (IMAC)
Phosphopeptides from trypic digestion were further enriched with the Magnetic Phosphopeptide Enrichment Kit (Clontech), according to the manufacturer's instructions but with a slight modification. First, the tryptic peptides were reconstituted in an appropriate volume of the binding/washing buffer and incubated with the washed and equilibrated beads for 30 min at room temperature by gentle shaking. The supernatant was then removed from the beads by a magnetic separator. The beads containing the phosphopeptides were washed three times with the wash buffer. Finally, the phosphopeptides were eluted three times using a total of 100 μl of elution buffer. The eluates were then filtered through an 0.22-μm filter and dried in a Speed Vac.
Nanoflow LC-MS/MS protein identification and database searches
The pTyr peptides enriched by IMAC were analyzed using an LTQ mass spectrometer (Thermo Electron Corp., San Jose, CA) equipped with a nanoelectrospray ion source. The m/z ratios of the peptides and their fragmented ions were recorded by the mass spectrometer. The peak lists for the MS2 and MS3 spectra were generated from the raw data by Bioworks version 3.3 (Thermo Electron) using the following parameters: the mass range was 600-3500, intensity threshold was 1000, and minimum ion count was 10. The generated peak lists were searched by the Sequent program (included in Bioworks) against the nonredundant human protein database of the human International Protein Index (IPI) (ipi.HUMAN.3.3.fasta). The MS/MS spectra were searched with a precursor ion mass tolerance of 2 Da and fragment ion mass tolerance of 1 Da. Full tryptic specificity was applied, two missed cleavages were allowed, and static modification was set for the alkylation of Cys with iodoacetamide (+57). To search the MS/MS data, dynamic modifications were set for oxidized Met (+16) and phosphorylated Ser, Thr, and Tyr (+80). Neutral losses of water and ammonia from the b and y ions were considered in the correlation analysis. To identify phosphopeptides on the basis of the MS/MS or MS/MS/MS spectra, the sequences must meet the following filter criteria: cross-correlation value (Xcorr) > 1.5, 2.0, and 2.5 for singly, doubly, and triply charged ions, respectively; uniqueness scores of matches (deltaCn) > 0.1; and peptide mass tolerance of 5 ppm.
Bioinformatics analysis of pTyr proteins
For functional annotation and protein-protein interaction (PPI) analysis, the identified pTyr proteins were submitted to the Human Protein Reference Database (HPRD). This database contains extensive information on human proteins, including domain architecture, protein functions, PPIs, posttranslational modifications (PTMs), enzyme-substrate relationships, subcellular localization, tissue expression, and disease association of genes [21–23]. This allows the identified pTyr proteins to be classified into subclasses based on their biological processes and molecular functions. The expression of these proteins was also evaluated under normal and liver cancer conditions using the records in the HPRD. Based on the PPI information available in the HPRD, a PPI network was generated using the Cytoscape version 2.6.1 software [24, 25]. This is an open-source bioinformatics software platform for visualizing molecular interaction networks and biological pathways. It allows these networks to be integrated with annotations, gene expression profiles, and other state data. Cytoscape contains some web plug-ins for downloading/linking a network from/to several databases such as pathwayCommons, IntAct, and NCBI Entrez Gene. Moreover, this software contains several plug-ins that allow computational analyses and functional enrichment, such as clusterMaker, BubbleRouter, and BinGO. In this study, functional clustering and signaling pathway analyses of proteins were carried out by running the BinGO, pathwayCommons, and BubbleRouter programs in Cytoscape. BinGO is a tool for determining the Gene Ontology (GO) categories that are statistically overrepresented in a set of genes or a subgraph of a biological network . It returns the correct p-value after using two different methods to account for multiple testing. In this study, the result was evaluated by the p-value from the Hypergeometric test, and the correct p-value was calculated using the Benjamini & Hochberg False Discovery Rate (FDR) correction.
RNAi and transfection
A 21-nt long double-stranded siRNA for FER was designed on the basis of reported data. It was derived from the human FER cDNA (accession no. J03358) 5'-AAA GAA ATT TAT GGC CCT GAG-3' (nt 84-104)  and was synthesized by Jikai Biotechnical Company (Shanghai, China). The selected siRNA sequences were submitted for a BLAST search against the human genome sequence to confirm the specificity of the siRNA. An unrelated silencing sequence was selected and synthesized as a negative control.
For siRNA transfection, 3 × 105 MHCC97H cells were seeded in a 6-well plate 1 day prior to transfection. Transfection was performed with the Lipofectamine 2000 Plus transfection agent (Invitrogen) according to the manufacturer's instructions. First, 200 pmol siRNA was diluted in 250 μl Opti-MEM (Gibco-Invitrogen) and mixed with 40 μl Plus transfection agent. This was left for 20 min at RT. Next, Lipofectamine 2000 was diluted in 250 μl Opti-MEM and left for 5 min at RT. The two solutions were then mixed and left at RT for 20 min. After aspirating the medium, the cells were washed twice with PBS and added to 1.5 ml of new Opti-MEM and transfection mixture. After transfection for 4-6 h, the medium was exchanged with the standard cell medium. The experiments with FER RNAi were initiated 48 h after transfection.
Cell invasion assay in vitro
The MHCC97H cell invasion assay was performed in a 24-well plate according to a previously described protocol but with slight modifications . Briefly, 100 μl of Matrigel (1 mg/ml) was added to the upper chamber of a 24-well transwell plate, and the plate was incubated at 37°C for at least 4-5 h to induce gelling. The upper chamber that was coated with Matrigel was washed three times using warm serum-free medium, and 200 μl of cell suspension containing 1 × 105 cells was placed in the chamber. Simultaneously, the lower chamber of the transwell plate was filled with 600 μl of the cell supernatant from 3T3 cells supplemented with 10% FBS. After cell invasion for 30 h at 37°C, the noninvaded cells at the top of the transwell plate were scraped off with a cotton swab. All invaded cells were stained with the Giemsa staining solution and counted under a microscope. The mean value of three independent experiments was used for the t-test to calculate the statistical significance.
TMA construction and immunohistochemical staining
A tissue microarray (TMA) was assembled using 100 HCC cases, consisting of 50 cases each of HCC with or without metastasis studied over a follow-up period of 2~5 years. For each case, 2 core samples of hepatoma tissue were acquired from a donor paraffin block provided by the Pathology Diagnosis Department of Zhongshan Hospital. Serial tissue sections (4 μm thick) were cut from the TMAs for immunohistochemical analysis.
For immunohistochemical staining, the slides were deparaffinized in xylene and rehydrated through a graded series of ethanol concentrations. Intrinsic peroxidase was blocked by using 3% hydrogen peroxide for 15 min. A solution of 5% BSA in PBST (PBS + 0.125% Tween 20) was used to block nonspecific antibody binding, and anti-FER antibodies (Sigma-ATLAS) were used at the concentration recommended by the manufacturer. The slides were kept overnight at 4°C. After washing three times with PBST for 5 min, the slides were incubated with the secondary antibody for 30 min at room temperature. Following three additional washes in TBST, the slides were developed by DAB staining. The sections were scanned at low magnification. The immunostaining score was estimated on a scale of 0 to 3 based on the percentage and intensity of the stained tumor cells, using the criterion given on the ATLAS web http://www.proteinatlas.org. Whether the stain was distributed on the membrane or in the cytoplasm was also recorded and assessed at high magnification. The immunoreactivity was scored semiquantitatively by counting the area and density of stained cells using the Image-Pro Plus 5.0 software. Manual correction was then performed to normalize the score. Statistical analysis was performed with the SPSS13.0 software using the nonparametric Mann-Whitney U test.
pTyr protein capture and the expression profiles of Hep3B and MHCC97H cells
Enrichment and identification of phosphopeptides
Functional annotation of pTyr proteins
Functional classification of identified pTyr proteins based on biological process in Hep3B and MHCC97H cell
GO-ID: biological process
nucleic acid metabolism
cell growth and maintenance
Functional classification of identified pTyr proteins based on molecule function in Hep3B and MHCC97H cell
GO-ID: molecular function
transcription associated protein
Translation regulatory protein
Integral membrane protein
DNA binding protein
RNA binding protein
Cytoskeletal associated protein
Calcium binding protein
Ubiquitin proteasome system protein
Protein interaction analysis
In the two simple networks, linker proteins, including CEBPB, EP300, MAPK1, MAPK3, MYC, PRKCB1, RPS6KA1, and SMARCA4, were shared. These were involved in some important signaling pathways such as the TNF-alpha-NF-kB signaling pathway, androgen-receptor signaling pathway, MAPK cascade, apoptosis pathways, Wnt-signaling pathways, cell cycle-G1 to S control, etc. These pathways play important roles in cell growth, differentiation, cell-cycle control, and apoptosis. The results suggested that the common pTyr proteins involved in these pathways may be associated with HCC pathogenesis.
Moreover, comparison of these two simple networks revealed that FER (a nonreceptor tyrosine kinase) was probably a protein of biological importance in HCC cell metastasis. It existed as only a dual function protein (root and linker-like protein) in these two simple networks. It linked four root proteins--CTNND1, CTTN, STAT3, and CAV1 (see highlighted diamond node and red edge in Figure 4B), in the MHCC97H network; however, it was absent in the Hep3B network. Interestingly, one each of these four proteins played a key role in cytoskeletal regulation, cell adhesion, signal regulation, and transportation. Thus, based on the results, it is reasonable to suppose that FER is an important pTyr protein and was therefore selected for sequential functional validation.
Functional clustering analysis
To fully predict the coherent function, all node proteins from the PPI networks of the MHCC97H and Hep3B cells were clustered according their GO attributes in biological process and signaling pathways.
Verification of the pTyr proteins
Bioinformatics analysis based on computer calculations and the application of biological software is a very effective and essential supplement in proteomics research. It is a powerful tool that has been extensively used for MS/MS data analysis, such as PPI studies, functional clustering, pathway mapping, and prediction of protein function and structure [11, 28–34]. In this study, we examined the expression profiles of pTyr proteins in two HCC cell lines (MHCC97H and Hep3B) that have different metastatic potentials. For this purpose, we used an LC-MS/MS-based proteomics technique. We also compared and analyzed the interactions and functions of these proteins by PPI and functional clustering analyses based on their GO attributes that were determined by biological process clustering and signaling pathway analysis. The results revealed that some cell functions related to cancer metastasis were significantly upregulated in HCC metastasis, especially those involved in cell motility, migration, localization, communication, antiapoptosis processes, and protein autophosphorylation. These alterations have been partly reported in previous studies on cancer metastasis [35–38]. High motility and migration are prerequisites for the successful metastasis of tumor cells and their transfer to the target site, penetration into the basement membrane and blood vessels, and movement from poorly oxygenated sites to rich oxygenated sites [3, 39]. Antiapoptosis is a pivotal mechanism by which cancer cells are protected from elimination by means of various steps of a metastatic process . At present, there are large amounts of data that highlight the importance of this process in cancer metastasis (reviewed in [40–43]). Protein amino acid autophosphorylation is a specific attribute of tyrosine kinase, and its upregulation in the highly metastatic MHCC97H cells confirmed that alteration of tyrosine phosphorylation was in fact involved in HCC metastasis. Western blot analysis of the pTyr protein profile also confirmed these results. More importantly, we found that alteration in cell communication was the most obvious cellular event in HCC metastasis. Since cell communication driven by signal transduction controls all cell behavior and activity, aberrations in signal transduction could be a crucial factor leading to HCC metastasis and could also trigger changes in cancer cell behavior. Therefore, it is very important to explore the events that occur during the activation and regulation of the signaling pathway in HCC metastasis. For this purpose, a pathway clustering analysis was performed for the node proteins of the PPI networks in Hep3B and MHCC97H cell lines. The results revealed that EGFR signal transduction, cytokine- and chemokine-mediated signaling, and the PI3K and JAK-STAT cascades were closely related with HCC metastasis since these processes were significantly upregulated. These analytical results were similar to those obtained for liver metastasis of breast cancer [11, 29]. EGFR is an Erb-family transmembrane receptor tyrosine kinase. This receptor is shared by multiple ligands, including EGF, TGF, EGFF-like factor, and amphiregulin . EGFR-mediated signaling has been implicated in a variety of human cancers and is a key regulator of the cell proliferation, migration, metastasis, angiogenesis, and antiapoptosis processes [45, 46]. Recently, some studies have reported that EGFR inhibitors are effective first-line therapeutic agents in the treatment of some metastatic cancers [47, 48]. EGFR is a potential therapeutic target in HCC treatment [49, 50]. The JAK-STAT cascade, which is another example, is a critical signaling pathway that plays an important role in cell proliferation, differentiation, survival, motility, and apoptosis . Recently, it was reported that sustained activation of the JAK-STAT cascade was involved in hepatocarcinogenesis and metastasis [52, 53]. The data showed that increasing activity of the JAK-STAT cascade was associated with aberrant methylation silencing of the suppressor of cytokine signaling (SOCS), which is a negative regulator of the JAK-STAT pathway . However, another study also suggested that constitutive activation of STAT3 was closely related to HCC metastasis and was the main factor leading to the upregulation of the JAK-STAT cascade . Consistent with these results, our MS/MS results also indicated STAT3 activation. Unexpectedly, the JNK cascade was found to be negatively associated with HCC metastasis, thereby deviating from its canonical functions. This indicates that the role of this cascade in HCC metastasis should be re-evaluated. Negative regulation of the JNK cascade was recently reported in prostate and ovarian cancers [56, 57]. Researchers showed that JNKK1, an upstream kinase of JNK, could persistently phosphorylate JNK and activate the stress-activated protein kinase signaling pathway (SAPK) to induce cell apoptosis and decrease tumor metastasis. Moreover, the SAPK pathway also showed a negative correlation with HCC metastasis in this study. Therefore, these two pathways might play synergetic roles in HCC metastasis. In other words, cluster analysis of signaling pathways may provide some important information for predicting the functions of the pTyr proteins involved in HCC metastasis. These results have been obtained by bioinformatics studies and need to be verified experimentally prior to practical application.
In our study, FER, a nonreceptor tyrosine kinase, was shown to be significantly involved in the HCC metastatic process. FER was initially discovered in 1988 during studies on the proto-oncogene protein Fes/Fps . Since then, its involvement has been reported in growth factors/cytokine-mediated signaling as well as in the integrin/E-cadherin-mediated signaling pathways. It also plays a critical role in cytoskeletal regulation, cell adhesion, migration, and proliferation [59–61]. In this study, we examined the total and phosphorylated forms of FER; these were found to be overexpressed in the MHCC97H cell line but not in the Hep3B cell line. Similar expression patterns were observed for CTNND1 and CAV1, which are related to FER, and the results were also validated by western blotting and MS/MS analyses. FER and CTNND1 were shown to be involved in cadherin and integrin-mediated cell adhesion. Under normal circumstances, FER could indirectly sustain CTNNB1 dephosphorylation to ensure cadherin-mediated adhesion stability. When FER is overexpressed and phosphorylated, it can directly induce CTNNB1 and CTNND1 phosphorylation, resulting in the loss of cadherin-mediated adhesion [61, 62]. This suggests that increasing metastasis may be associated with CTNNB1 in some cancers. Moreover, CTNND1 had been implicated in the metastasis and pathogenesis of several human cancers . It was shown that overexpression and phosphorylation of CTNND1 in the cytoplasm could promote cadherin-deficient tumor metastasis by regulating the activity of the small GTPase [64, 65]. CAV1 is an important marker protein of caveolae and regulates signal transduction as a scaffolding protein. Recently, CAV1 was found to be an independent predictor of decreased survival in breast and rectal cancers and was significantly associated with the presence of distant metastasis in colon cancer patients . CAV1 could also sustain cadherin-mediated adhesion stability. It functioned by modulating the level and/or subcellular distribution of cadherin and CTNND1 by inhibiting Src kinase activity . Nevertheless, FER was identified as a Src substrate and is involved in tumor transformation . In this study, these three proteins displayed similar expression patterns in the two cell lines studied and also interacted directly in the MHHCC97H network. Therefore, we hypothesize that FER may be a key regulator in the adhesion event involving these three proteins and may participate in HCC metastasis. We also examined the influence of FER on cell invasion activity in vitro. The data illustrated that the knock-down of FER by RNAi significantly reduced MHCC97H cell invasion activity, suggesting that FER could positively contribute to HCC metastasis. To verify this, we further examined FER expression in HCC tumor tissues from patients with diverse distant metastasis outcomes after tumor excision. The results showed that FER overexpression frequently occurred in tumor cells with distant pulmonary metastasis, indicating that FER is strongly associated with HCC distant pulmonary metastasis.
Once it is confirmed that FER is a potential regulator in HCC metastasis, the next step is to understand the mechanism by which it regulates HCC cell metastasis. To date, there are few reports on the functional regulation of FER in cancer, and the main focus has been on cell adhesion. FER was shown to play a key role in the coordinate regulation of E-cadherin-mediated cell-cell adhesion and integrin-mediated focal adhesion. It could move between the two adhesion pathways to trigger adhesion transition [59, 61]. In a study on FER function using the Trojan peptide, researchers showed that FER that had dissociated from the cadherin complex could translocate to the integrin complex where it reduced p130CAS phosphorylation and interrupted integrin-mediated focal adhesion by affecting the phosphorylation of p130CAS binding partners, including PTP-PEST, PTP1B, FAK, and Crk . FER was also reported to be an upstream tyrosine kinase for CTTN (cortactin) as well as Src and Fyn [68, 69]. Phosphorylation of CTTN by FER is very critical for its recruitment to the cadherin and integrin complex . CTTN mainly participates in cytoskeletal regulation and plays a pivotal role in tumor metastasis [71, 72]. Recently, CTTN was shown to be an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation . In another study, it was shown that phosphorylation of tyrosine residues in CTTN was strongly associated with the potential to induce metastasis in nude mice . Whether CTTN phosphorylation by FER also has the same effects in HCC metastasis needs to be confirmed in future studies.
The results of this study suggested that FER is involved in HCC distant metastasis, and we have discussed the main mechanism and signaling pathways associated with FER functional regulation. The results from bioinformatics analysis also imply that FER is altered in MHCC97H cells in comparison with Hep3B cells. As a new functional molecule, the effect of FER on HCC metastasis remains unknown. It is possible that FER can alter the metastatic potential of HCC cells by one or several of the mechanisms mentioned here. Further studies are required to explore the exact role of FER in HCC cell invasion and metastasis. These would be both exciting and challenging.
The tyrosine phosphorylation data presented in this study is a useful resource for studying HCC metastasis and is an effective supplement for the PTyr database reported. Many of the identified pTyr proteins, including protein kinases and proteinases, could be useful for selecting intervention targets in future studies. The presence of multiple molecules and signaling pathways that are overrepresented in HCC cells with high metastatic potential suggests that HCC metastasis is a complex process and that the biological strategies for HCC metastasis treatment should be customized. In this study, FER was shown to be an important protein in HCC metastasis. We hope to obtain more evidence for the role of FER and its mechanism of action in HCC metastasis. This molecule may be a new drug target in future HCC therapy.
We would like to thank Mr Yao Jun (Fudan University, Shanghai, China) for LC-MS/MS identification and Mr Yang Zhang (Fudan University, Shanghai, China) for assistance with bioinformatics analysis. This work was supported by grants from National Natural Science Foundation of China (NO.30672416) and National High Technology Research and Development Program of China (863 Program) (NO. 2006AA02A308).
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.View ArticlePubMedGoogle Scholar
- Mareel M, Leroy A: Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003, 83 (2): 337-376.View ArticlePubMedGoogle Scholar
- Nguyen DX, Massague J: Genetic determinants of cancer metastasis. Nat Rev Genet. 2007, 8 (5): 341-352. 10.1038/nrg2101.View ArticlePubMedGoogle Scholar
- Pawson T, Scott JD: Signaling through scaffold, anchoring, and adaptor proteins. Science. 1997, 278 (5346): 2075-2080. 10.1126/science.278.5346.2075.View ArticlePubMedGoogle Scholar
- Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003, 3 (1): 55-63. 10.1038/nrc967.View ArticlePubMedGoogle Scholar
- Steeg PS: New insights into the tumor metastatic process revealed by gene expression profiling. Am J Pathol. 2005, 166 (5): 1291-1294.View ArticlePubMedPubMed CentralGoogle Scholar
- Cairns RA, Khokha R, Hill RP: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med. 2003, 3 (7): 659-671. 10.2174/1566524033479447.View ArticlePubMedGoogle Scholar
- Baselga J: Targeting tyrosine kinases in cancer: the second wave. Science. 2006, 312 (5777): 1175-1178. 10.1126/science.1125951.View ArticlePubMedGoogle Scholar
- Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature. 2001, 411 (6835): 355-365. 10.1038/35077225.View ArticlePubMedGoogle Scholar
- Chong PK, Lee H, Kong JW, Loh MC, Wong CH, Lim YP: Phosphoproteomics, oncogenic signaling and cancer research. Proteomics. 2008, 8 (21): 4370-4382. 10.1002/pmic.200800051.View ArticlePubMedGoogle Scholar
- Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, et al: Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008, 7 (4): 1508-1517. 10.1021/pr7008127.View ArticlePubMedGoogle Scholar
- Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P: Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008, 15 (4): 1008-1014. 10.1245/s10434-007-9705-0.View ArticlePubMedGoogle Scholar
- Siuti N, Kelleher NL: Decoding protein modifications using top-down mass spectrometry. Nat Methods. 2007, 4 (10): 817-821. 10.1038/nmeth1097.View ArticlePubMedPubMed CentralGoogle Scholar
- Domon BAR: Mass Spectrometry and Protein Analysis. Science. 2006, 312 (5771): 212-217. 10.1126/science.1124619.View ArticlePubMedGoogle Scholar
- Hjerrild M, Gammeltoft S: Phosphoproteomics toolbox: computational biology, protein chemistry and mass spectrometry. FEBS Lett. 2006, 580 (20): 4764-4770. 10.1016/j.febslet.2006.07.068.View ArticlePubMedGoogle Scholar
- Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001, 7 (5): 630-636.PubMedPubMed CentralGoogle Scholar
- Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007, 26 (44): 6361-6371. 10.1038/sj.onc.1210463.View ArticlePubMedGoogle Scholar
- Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN, Lau CK, Li ML, Tam KH, Lam CT, Poon RT, et al: Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008, 47 (3): 919-928. 10.1002/hep.22082.View ArticlePubMedGoogle Scholar
- Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 2008, 48 (6): 1834-1842. 10.1002/hep.22531.View ArticlePubMedGoogle Scholar
- Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, Gao MD, Liu KY: Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC Cancer. 2009, 9: 100-10.1186/1471-2407-9-100.View ArticlePubMedPubMed CentralGoogle Scholar
- Navarro JD, Talreja N, Peri S, Vrushabendra BM, Rashmi BP, Padma N, Surendranath V, Jonnalagadda CK, Kousthub PS, Deshpande N, et al: BioBuilder as a database development and functional annotation platform for proteins. BMC Bioinformatics. 2004, 5: 43-10.1186/1471-2105-5-43.View ArticlePubMedPubMed CentralGoogle Scholar
- Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi TK, Gronborg M, et al: Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res. 2003, 13 (10): 2363-2371. 10.1101/gr.1680803.View ArticlePubMedPubMed CentralGoogle Scholar
- Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, Gandhi TK, Chandrika KN, Deshpande N, Suresh S, et al: Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res. 2004, D497-501. 10.1093/nar/gkh070. 32 DatabaseGoogle Scholar
- Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13 (11): 2498-2504. 10.1101/gr.1239303.View ArticlePubMedPubMed CentralGoogle Scholar
- Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, et al: Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007, 2 (10): 2366-2382. 10.1038/nprot.2007.324.View ArticlePubMedPubMed CentralGoogle Scholar
- Maere S, Heymans K, Kuiper M: BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005, 21 (16): 3448-3449. 10.1093/bioinformatics/bti551.View ArticlePubMedGoogle Scholar
- Pasder O, Shpungin S, Salem Y, Makovsky A, Vilchick S, Michaeli S, Malovani H, Nir U: Downregulation of Fer induces PP1 activation and cell-cycle arrest in malignant cells. Oncogene. 2006, 25 (30): 4194-4206. 10.1038/sj.onc.1209695.View ArticlePubMedGoogle Scholar
- Knutson JR, Iida J, Fields GB, McCarthy JB: CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell. 1996, 7 (3): 383-396.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin B, Sanz R, Aragues R, Oliva B, Sierra A: Functional clustering of metastasis proteins describes plastic adaptation resources of breast-cancer cells to new microenvironments. J Proteome Res. 2008, 7 (8): 3242-3253. 10.1021/pr800137w.View ArticlePubMedGoogle Scholar
- Berger SI, Posner JM, Ma'ayan A: Genes2Networks: connecting lists of gene symbols using mammalian protein interactions databases. BMC Bioinformatics. 2007, 8: 372-10.1186/1471-2105-8-372.View ArticlePubMedPubMed CentralGoogle Scholar
- Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, Pandey A, Cole PA: Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci USA. 2006, 103 (26): 9773-9778. 10.1073/pnas.0603948103.View ArticlePubMedPubMed CentralGoogle Scholar
- Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006, 24 (10): 1285-1292. 10.1038/nbt1240.View ArticlePubMedGoogle Scholar
- Madoz-Gurpide J, Canamero M, Sanchez L, Solano J, Alfonso P, Casal JI: A proteomics analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics. 2007, 6 (12): 2150-2164. 10.1074/mcp.M700006-MCP200.View ArticlePubMedGoogle Scholar
- Birzele F, Gewehr JE, Csaba G, Zimmer R: Vorolign--fast structural alignment using Voronoi contacts. Bioinformatics. 2007, 23 (2): e205-211. 10.1093/bioinformatics/btl294.View ArticlePubMedGoogle Scholar
- Hatakeyama H, Kondo T, Fujii K, Nakanishi Y, Kato H, Fukuda S, Hirohashi S: Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics. 2006, 6 (23): 6300-6316. 10.1002/pmic.200600488.View ArticlePubMedGoogle Scholar
- Chen N, Sun W, Deng X, Hao Y, Chen X, Xing B, Jia W, Ma J, Wei H, Zhu Y, et al: Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics. 2008, 8 (23-24): 5108-5118. 10.1002/pmic.200800280.View ArticlePubMedGoogle Scholar
- Al-Ghoul M, Bruck TB, Lauer-Fields JL, Asirvatham VS, Zapata C, Kerr RG, Fields GB: Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res. 2008, 7 (9): 4107-4118. 10.1021/pr800174k.View ArticlePubMedGoogle Scholar
- Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, Wong CH, Wong CY, Shah N, Lim YP: Novel Breast Cancer Metastasis-Associated Proteins. J Proteome Res. 2009, 8 (2): 583-594. 10.1021/pr8007368.View ArticlePubMedGoogle Scholar
- Silletti S, Paku S, Raz A: Tumor cell motility and metastasis: Autocrine motility factor as an example of ecto/exoenzyme cytokines. Pathol Oncol Res. 1997, 3 (3): 230-254. 10.1007/BF02899927.View ArticlePubMedGoogle Scholar
- Simpson CD, Anyiwe K, Schimmer AD: Anoikis resistance and tumor metastasis. Cancer Lett. 2008, 272 (2): 177-185. 10.1016/j.canlet.2008.05.029.View ArticlePubMedGoogle Scholar
- Townson JL, Naumov GN, Chambers AF: The role of apoptosis in tumor progression and metastasis. Curr Mol Med. 2003, 3 (7): 631-642. 10.2174/1566524033479483.View ArticlePubMedGoogle Scholar
- Cao L, Han L, Zhang Z, Li J, Qu Z, Du J, Liang X, Liu Y, Liu H, Shi Y, et al: Involvement of anoikis-resistance in the metastasis of hepatoma cells. Exp Cell Res. 2009, 315 (7): 1148-1156. 10.1016/j.yexcr.2008.11.010.View ArticlePubMedGoogle Scholar
- Abend M, Port M, Schmelz HU, Kraft K, Sparwasser C: Significance of apoptosis in metastasizing testis tumors. Urol Res. 2004, 32 (1): 28-35. 10.1007/s00240-003-0370-x.View ArticlePubMedGoogle Scholar
- Carpenter G: Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987, 56: 881-914. 10.1146/annurev.bi.56.070187.004313.View ArticlePubMedGoogle Scholar
- Grandal MV, Madshus IH: Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med. 2008, 12 (5A): 1527-1534. 10.1111/j.1582-4934.2008.00298.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Vallbohmer D, Lenz HJ: Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer. 2005, 5 (Suppl 1): S19-27. 10.3816/CCC.2005.s.003.View ArticlePubMedGoogle Scholar
- Lee JJ, Chu E: First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer. 2007, 6 (Suppl 2): S42-46. 10.3816/CCC.2007.s.001.View ArticlePubMedGoogle Scholar
- Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim JS, Langley RR, Fan D, Wang X, Do KA, Kim SJ, et al: Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis. 2008, 25 (4): 477-489. 10.1007/s10585-008-9153-7.View ArticlePubMedGoogle Scholar
- Hopfner M, Schuppan D, Scherubl H: Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol. 2008, 14 (1): 1-14. 10.3748/wjg.14.1.View ArticlePubMedPubMed CentralGoogle Scholar
- Furuse J: Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol. 2008, 67 (1): 8-15. 10.1016/j.critrevonc.2008.02.009.View ArticlePubMedGoogle Scholar
- Hebenstreit D, Horejs-Hoeck J, Duschl A: JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 2005, 18 (4): 243-249. 10.1358/dnp.2005.18.4.908658.View ArticlePubMedGoogle Scholar
- Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67 (6): 2497-2507. 10.1158/0008-5472.CAN-06-3075.View ArticlePubMedPubMed CentralGoogle Scholar
- Smirnova OV, Ostroukhova TY, Bogorad RL: JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?. World J Gastroenterol. 2007, 13 (48): 6478-6491. 10.3748/wjg.13.6478.View ArticlePubMedPubMed CentralGoogle Scholar
- Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T, Yoshikawa H: Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005, 24 (42): 6406-6417.PubMedGoogle Scholar
- Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Masuya M, Takei Y: Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2007, 363 (3): 738-744. 10.1016/j.bbrc.2007.09.049.View ArticlePubMedGoogle Scholar
- Hickson JA, Huo D, Griend Vander DJ, Lin A, Rinker-Schaeffer CW, Yamada SD: The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006, 66 (4): 2264-2270. 10.1158/0008-5472.CAN-05-3676.View ArticlePubMedGoogle Scholar
- Griend Vander DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW: Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 2005, 65 (23): 10984-10991. 10.1158/0008-5472.CAN-05-2382.View ArticleGoogle Scholar
- Letwin K, Yee SP, Pawson T: Novel protein-tyrosine kinase cDNAs related to fps/fes and eph cloned using anti-phosphotyrosine antibody. Oncogene. 1988, 3 (6): 621-627.PubMedGoogle Scholar
- Greer P: Closing in on the biological functions of Fps/Fes and Fer. Nat Rev Mol Cell Biol. 2002, 3 (4): 278-289. 10.1038/nrm783.View ArticlePubMedGoogle Scholar
- Orlovsky K, Theodor L, Malovani H, Chowers Y, Nir U: Gamma interferon down-regulates Fer and induces its association with inactive Stat3 in colon carcinoma cells. Oncogene. 2002, 21 (32): 4997-5001. 10.1038/sj.onc.1205624.View ArticlePubMedGoogle Scholar
- Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia de Herreros A, Dunach M: p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell Biol. 2003, 23 (7): 2287-2297. 10.1128/MCB.23.7.2287-2297.2003.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, Lilien J, Balsamo J: Continuous association of cadherin with beta-catenin requires the non-receptor tyrosine-kinase Fer. J Cell Sci. 2004, 117 (Pt 15): 3207-3219. 10.1242/jcs.01174.View ArticlePubMedGoogle Scholar
- Reynolds AB, Roczniak-Ferguson A: Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004, 23 (48): 7947-7956. 10.1038/sj.onc.1208161.View ArticlePubMedGoogle Scholar
- Davis MA, Ireton RC, Reynolds AB: A core function for p120-catenin in cadherin turnover. J Cell Biol. 2003, 163 (3): 525-534. 10.1083/jcb.200307111.View ArticlePubMedPubMed CentralGoogle Scholar
- Anastasiadis PZ, Reynolds AB: Regulation of Rho GTPases by p120-catenin. Curr Opin Cell Biol. 2001, 13 (5): 604-610. 10.1016/S0955-0674(00)00258-1.View ArticlePubMedGoogle Scholar
- Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, Griffith OL, Chan SK, Jones SJ, Leung SP, Masoudi H, et al: Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 2008, 68 (20): 8210-8220. 10.1158/0008-5472.CAN-08-0343.View ArticlePubMedGoogle Scholar
- Miotti S, Tomassetti A, Facetti I, Sanna E, Berno V, Canevari S: Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol. 2005, 167 (5): 1411-1427.View ArticlePubMedPubMed CentralGoogle Scholar
- Li H, Leung TC, Hoffman S, Balsamo J, Lilien J: Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J Cell Biol. 2000, 149 (6): 1275-1288. 10.1083/jcb.149.6.1275.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim L, Wong TW: Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J Biol Chem. 1998, 273 (36): 23542-23548. 10.1074/jbc.273.36.23542.View ArticlePubMedGoogle Scholar
- El Sayegh TY, Arora PD, Laschinger CA, Lee W, Morrison C, Overall CM, Kapus A, McCulloch CA: Cortactin associates with N-cadherin adhesions and mediates intercellular adhesion strengthening in fibroblasts. J Cell Sci. 2004, 117 (Pt 21): 5117-5131. 10.1242/jcs.01385.View ArticlePubMedGoogle Scholar
- Daly RJ: Cortactin signalling and dynamic actin networks. Biochem J. 2004, 382 (Pt 1): 13-25.View ArticlePubMedPubMed CentralGoogle Scholar
- Patel AS, Schechter GL, Wasilenko WJ, Somers KD: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene. 1998, 16 (25): 3227-3232. 10.1038/sj.onc.1201850.View ArticlePubMedGoogle Scholar
- Clark ES, Whigham AS, Yarbrough WG, Weaver AM: Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res. 2007, 67 (9): 4227-4235. 10.1158/0008-5472.CAN-06-3928.View ArticlePubMedGoogle Scholar
- Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X: Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res. 2001, 61 (18): 6906-6911.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/366/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.